ClinicalTrials.gg
CompletedNCT00431678Updated Dec 17, 2014

Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia

A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Levofloxacin + Ceftriaxone in Pneumonia, sponsored by Bayer. Completed at 97 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-17.

Primary conditionCommunity-Acquired PneumoniaRegistry: PneumoniaReclassifiedWhy we changed it
Registry
Pneumonia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Community-Acquired Pneumonia
Why
  1. The study's title name Community-Acquired Pneumonia, a narrower term within Pneumonia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
738
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Community-Acquired Pneumonia with a site in France — 11 open to participants now, 11 under way, 5 of them phase 3. Community-Acquired Pneumonia · France.

Enrollment
7th of 26
738 · median 327
Started
2004
the only one that year
Phase 3
9 of 40
5 open now
Registered
1st of 40
by date
Lead sponsor
2 of 40
Bayer

Among the 40 studies in Community-Acquired Pneumonia with a site in France, this one is the 7th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2004, is one of 9 in phase 3, and was the 1st registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

11 of the 40 studies in Community-Acquired Pneumonia with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Community-Acquired Pneumonia with a site in France, or all of them as a file.
02

Study summary

Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in 17 countries to determine if this treatment regimen is safe and effective in treating hospitalized adult patients with community-acquired pneumonia. 748 patients were participated in the study over an 18 months period. Individual patient involvement in the study was approximately 4-6 weeks. Moxifloxacin was compared to a combination treatment regimen of high dose intravenous ceftriaxone plus high dose intravenous levofloxacin followed by high dose oral levofloxacin.

03

Conditions studied

  • Pneumonia

Browse trials for

Keywords

  • Community-acquired Pneumonia
04

In context

Community-Acquired Pneumonia Reclassified

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

This study's enrollment of 738 is above the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Community-Acquired Pneumonia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or above
  • All of the following signs and symptoms of pneumonia:

    • Fever (core/ rectal/ tympanic temperature >/= 38.5°C or axillary/ oral/ cutaneous temperature >/= 38.0°C) or hypothermia (core/ rectal/ tympanic temperature \</= 35.5°C or axillary/ oral/ cutaneous temperature \</= 35.0°C)
    • White blood cell (WBC) count > 10,000/µL, or >/= 15% immature neutrophils (bands), regardless of the peripheral WBC count, or total WBC count \< 4,500/µL
    • The presence of at least 2 of the following symptoms: - Cough- Purulent sputum production
  • Dyspnoea or tachypnoea (respiratory rate > 20 breaths/minute)
  • Rigors and/or chills- Chest pain
  • Auscultatory findings on pulmonary examination of rales/crackles and/or evidence of pulmonary consolidationAND
  • Radiological evidence of (an) infiltrate(s) consistent with bacterial pneumonia at baseline or within 24 hours following enrolment
  • Fine score >/= 71 (i.e. Pneumonia PSI risk Class III, IV or V, requiring hospitalisation for the treatment of CAP)
  • Written obtained from the patient or a next-of-kin

Exclusion criteria

Exclusion Criteria:

  • Known to fluoroquinolones, or other quinolones, and/or to beta-lactams, or any of the
  • Female patients who are pregnant or lactating
  • History of tendon disease/disorder related to quinolone treatment
  • Known congenital or documented-acquired ; concomitant use of drugs, reported to increase the QT interval; uncorrected hypokalaemia; bradycardia; clinically relevant heart failure with reduced left
  • ventricular ; previous history of symptomatic arrhythmias
  • History of epilepsy- Known glucose-6-phosphate dehydrogenase deficiency
  • Known severe impaired liver function (i.e. C), (refer to Section 10.4 for definition) or transaminases increase > 5 fold - Hospitalisation for > 48 hours before developing pneumonia, or discharge from hospital \< 30 days prior- Systemic antibacterial therapy for more than 24 hours within 14 days of enrolment
  • Patients requiring concomitant systemic antibacterial agents
  • Known structural lung disease (e.g. cystic fibrosis, bronchiectasis, or lung cancer), or other known conditions (e.g. malnutrition) predisposing to infection with nosocomial-like organisms such as Pseudomonas aeruginosa
  • Lung abscess, pleural empyema, risk factors for aspiration pneumonia (e.g. recent stroke, head injury, dementia)
  • Known rapidly fatal underlying disease (death expected within 6 months)
  • Known or suspected active tuberculosis or endemic fungal infection- Neutropenia ( \< 1,000/µL) caused by therapy or
  • Patients known to have AIDS ( \< 200/µL) or -seropositive patients receiving HAART
  • Previous enrolment in this study
  • Participation in any clinical drug study within the previous 4 weeks
  • Patient with pre-terminal renal failure ( \< 10 mL/min) and patients undergoing haemodialysis
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
738 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

  • Active comparator
    Arm 2

    Drug: Levofloxacin + Ceftriaxone

Interventions

  • Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)

  • DrugLevofloxacin + Ceftriaxone

    Drug pages: Levofloxacin · Ceftriaxone

    Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).

07

What researchers measure

Primary outcomes

  1. Clinical response

    Time frame: 5 to 7 days after last dose of study medication

Secondary outcomes

  1. Clinical and bacteriological response

    Time frame: At the day of switch from intravenous to oral therapy

  2. Clinical and bacteriological response on treatment

    Time frame: At day 3 to 5

  3. Clinical and bacteriological response

    Time frame: At the end of treatment

  4. Bacteriological response

    Time frame: 5-7 days after end of treatment

  5. Mortality attributable to pneumonia

    Time frame: 5-7 days after end of treatment

  6. Clinical and bacteriological response

    Time frame: At days 21 to 28 after end of treatment

  7. Symptoms course of community-acquired pneumonia

    Time frame: at defined visits

  8. Adverse Event Collection

    Time frame: all visits

08

Study locations

97 sites
  • Vicente López, Buenos Aires B1602DOH, Argentina
  • Buenos Aires, Capital Federal C1118AAT, Argentina
  • Buenos Aires, Capital Federal C1120AAF, Argentina
  • Buenos Aires, Capital Federal C1180AAX, Argentina
  • Buenos Aires, Capital Federal C1431FWO, Argentina
  • Bruxelles - Brussel, 1070, Belgium
  • Bruxelles - Brussel, 1200, Belgium
  • Leuven, 3000, Belgium
  • Liege, 4000, Belgium
  • Namur, 5000, Belgium
  • Temuco, IX Region, Chile
  • Viña del Mar, V Region, Chile
  • Santiago de Chile, Chile
  • Santiago, Chile
  • Bogotá, Colombia
  • Bucaramanga, Colombia
  • Santafé de Bogotá, Colombia
  • Agen, 47923, France
  • Aix-en-provence, 13616, France
  • Argenteuil, 95107, France
  • Avignon, 84000, France
  • Belfort, 90016, France
  • Bordeaux, 33000, France
  • Brive-la-gaillarde, 19100, France
  • Paris, 75014, France
  • Saint-gaudens, 31806, France
  • Toulon, 83056, France
  • Vesoul, 70014, France
  • Bochum, Nordrhein-Westfalen 44789, Germany
  • Bochum, Nordrhein-Westfalen 44791, Germany
  • Lüdenscheid, Nordrhein-Westfalen 58515, Germany
  • Paderborn, Nordrhein-Westfalen 33098, Germany
  • Halle, Sachsen-Anhalt 06112, Germany
  • Magdeburg, Sachsen-Anhalt 39112, Germany
  • Berlin, 10117, Germany
  • Berlin, 13353, Germany
  • Rio, Patras 265 04, Greece
  • Athens, 11527, Greece
  • Thessaloniki, 546 36, Greece
  • Afula, 18101, Israel
  • Ashkelon, 78306, Israel
  • Holon, 58100, Israel
  • Tel Aviv, 64239, Israel
  • Tel Hashomer, 52621, Israel
  • Kaunas, 45130, Lithuania
  • Kaunas, 47144, Lithuania
  • Vilnius, LT-2001, Lithuania
  • Vilnius, LT-2006, Lithuania
  • Toluca, Edo. de México 50130, Mexico
  • Guadalajara, Jalisco 44280, Mexico
  • Monterrey, Nuevo León 64460, Mexico
  • México, D.F., 02290, Mexico
  • México, D.F., 07760, Mexico
  • México, D.F., 14000, Mexico
  • México, D.F., 14080, Mexico
  • Eindhoven, Noord Brabant 5623 EJ, Netherlands
  • Den Bosch, 5211 RB, Netherlands
  • EDE, 6716 RP, Netherlands
  • Harderwijk, 3844 DG, Netherlands
  • Heerlen, 6419 PC, Netherlands
  • Callao, 02, Peru
  • Lima Cercado, LIMA 1, Peru
  • Lima, 01, Peru
  • Bydgoszcz, 85-326, Poland
  • Gdansk, 80-803, Poland
  • Krakow, 30-501, Poland
  • Lodz, 91-425, Poland
  • Warszawa, 00-909, Poland
  • Warszawa, 01-138, Poland
  • Wroclaw, 50-417, Poland
  • Lisboa, 1769-001, Portugal
  • Bloemfontein, Free State, South Africa
  • Bloemfontein, Freestate 9300, South Africa
  • Brits, Gauteng 0250, South Africa
  • Johannesburg, Gauteng 2132, South Africa
  • Pretoria, Gauteng 0083, South Africa
  • Cape Town, Western Cape, South Africa
  • Somerset West, Western Cape 7130, South Africa
  • Huesca, Aragón 22004, Spain
  • L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Alcalá de Henares, Madrid 28805, Spain
  • Barcelona, 08003, Spain
  • Barcelona, 08036, Spain
  • Guadalajara, 19002, Spain
  • Madrid, 28008, Spain
  • Valencia, 46014, Spain
  • Jönköping, 551 85, Sweden
  • Kalmar, 391 85, Sweden
  • Karlstad, 651 85, Sweden
  • Skövde, 541 85, Sweden
  • Middlesborough, Cleveland TS4 3BW, United Kingdom
  • Dumfries, Dumfries and Galloway DG1 4EP, United Kingdom
  • Hull, Humberside HU3 2JZ, United Kingdom
  • Edinburgh, Lothian EH4 2XU, United Kingdom
  • Rotherham, South Yorkshire S60 2UD, United Kingdom
  • Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Newcastle Upon Tyne, Tyne and Wear NE7 7DN, United Kingdom
09

References and documents

Publications

  • Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC; MOTIV (MOxifloxacin Treatment IV) Study Group. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clin Infect Dis. 2008 May 15;46(10):1499-509. doi: 10.1086/587519. PubMed 18419482 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Jul 2005 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2007
First posted
Feb 6, 2007
Start
Jan 2004
Primary completionActual
Jul 2005
CompletionActual
Jul 2005
Last update
Dec 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00431678
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 6, 2007
Start date
Jan 2004
Primary completion
Jul 2005
Completion
Jul 2005
Last update
Dec 17, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion